🧾 What This Document Is

This is an SEC Form 8-K filing from Kezar Life Sciences. It contains the official legal contracts for a major corporate event: Kezar is being acquired by Aurinia Pharma.

Think of it like the final paperwork you sign when selling a house. It doesn't just say "we're being bought"—it lays out the exact rules, promises, and procedures for the sale.

👉 Why it matters: This isn't just news; it's the binding blueprint for how Kezar's stockholders will sell their shares and what happens to the company next.

🏢 What The Company Does

In simple terms, Kezar Life Sciences is a clinical-stage biotechnology company. They research and develop new drugs, primarily for cancer and autoimmune diseases. As of this filing, they are in the development stage, meaning they likely have experimental therapies in clinical trials but may not yet have a product on the market generating significant revenue.

🤝 The Deal: Acquisition by Aurinia

Kezar is being acquired by Aurinia Pharma U.S., Inc. (a subsidiary of Aurinia Pharmaceuticals Inc.). The deal is structured as a "tender offer" followed by a merger.

Here's the step-by-step process:

The Tender Offer: Aurinia will make a direct cash offer to buy all of Kezar's outstanding shares.
The Price: Stockholders will receive $6.955 per share in cash, plus one Contingent Value Right (CVR). The CVR is like a potential bonus ticket that could pay out more cash later if certain future events happen (related to Kezar's former pipeline or assets).
The Merger: Once enough shares are tendered, the companies will merge, with Kezar becoming a part of Aurinia. Any remaining shares not sold in the offer will be converted into the same deal ($6.955 + CVR).

💰 The Price Tag & Financial Mechanics

The $6.955 per share cash amount isn't random. It's based on a key calculation: "Closing Net Cash."

This is Kezar's estimated total cash and securities minus its debts, unpaid transaction costs, and future wind-down costs. The deal assumes Kezar has about $50 million in net cash at closing.

👉 Why this matters for investors: Your payout is tied to the final cash balance. If Kezar's net cash is higher than $50 million at closing, the price per share could be adjusted upward. If it's lower, it could be adjusted downward.

🚀 What Happens Next: The Wind-Down

This is a crucial part of the story. The merger agreement explicitly states that after the deal closes, Kezar will wind down its operations. This includes:

Closing down clinical studies.
Settling lease obligations for its lab/office space.
Paying remaining costs related to its former clinical pipeline (which were assigned to a CVR).

👉 The signal: This is an acquisition for Kezar's cash and remaining asset value, not for its ongoing research business. Aurinia is buying the company's financial resources and potentially some legacy assets, while Kezar's active operations are being terminated.

⚖️ Big Picture: Strengths & Risks

👍 Strengths / Positives:

Guaranteed Cash Offer: Stockholders get a clear, immediate cash value for their shares.
Certainty: The tender process is usually faster than a traditional shareholder vote.
Upside Potential (via CVR): The CVR provides a chance for additional future payments if certain assets generate value.

⚠️ Risks / Considerations:

CVR Uncertainty: The future payments from the CVR are not guaranteed and depend on complex future events. They could be worth little or nothing.
Deal Completion Risk: The offer has conditions (like regulatory approval) that must be met. If they aren't, the deal could be canceled.
End of the Road: For Kezar as a standalone research company, this deal represents the conclusion of its current strategic path.

🔮 What's Next & Key Dates

The tender offer will be launched and remain open for at least 20 business days.
If the offer is successful, the companies aim to complete the merger shortly afterward.
Kezar's stock will be delisted from the Nasdaq exchange once the merger is complete.

🧠 The Analogy

Selling your house "as-is" with a potential future bonus. You get a guaranteed cash offer today based on the current value of the property (Kezar's net cash). But, you also get a "contingent note" (the CVR) from the buyer saying, "If I discover valuable antique fixtures in the walls during renovation, I'll pay you a slice of that profit later." The main value is in the immediate sale, with a small chance of extra money down the line.

📇 Key Contacts & People

The signing executives for each party are:

For Kezar Life Sciences, Inc.:
- Christopher Kirk, Ph.D., Chief Executive Officer
For Aurinia Pharma U.S., Inc. and Aurinia Merger Sub, Inc.:
- Kevin Tang, Chief Executive Officer

(Note: The Tender Agreement also lists stockholder details on a confidential Schedule 1, which is not included in this public filing.)

🧩 Final Takeaway

This filing details the end of Kezar Life Sciences as an independent, operating biotech company. It is being acquired for its cash balance (~$50M) and wound down. Kezar stockholders will receive a fixed cash price plus a contingent, uncertain future payment, marking a clear exit event for the firm.

Kezar Life Sciences, Inc. — 8-K Filing